Corcept Therapeutics Inc
XBER:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
XBER:HTD
|
US |
|
Third Coast Bancshares Inc
NASDAQ:TCBX
|
US |
|
A
|
Abeona Therapeutics Inc
F:PCJP
|
US |
|
Heineken NV
OTC:HEINY
|
NL |
|
I
|
Imperial Brands PLC
F:ITB
|
UK |
|
R
|
Resilient Reit Ltd
JSE:RES
|
ZA |
Wall St Price Targets
HTD Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HTD is 71.07 EUR with a low forecast of 29.37 EUR and a high forecast of 100.75 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HTD's stock price target?
Price Target
71.07
EUR
According to Wall Street analysts, the average 1-year price target for HTD is 71.07 EUR with a low forecast of 29.37 EUR and a high forecast of 100.75 EUR.
What is the Revenue forecast for Corcept Therapeutics Inc?
Projected CAGR
20%
Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 20%.
What is the Gross Profit forecast for Corcept Therapeutics Inc?
Projected CAGR
20%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 52%. The projected CAGR for the next 8 years is 20%.
What is the Operating Income forecast for Corcept Therapeutics Inc?
Projected CAGR
65%
The compound annual growth rate for Operating Income over the next 8 years is 65%.
What is the Pre-Tax Income forecast for Corcept Therapeutics Inc?
Projected CAGR
150%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 150%.
What is the Net Income forecast for Corcept Therapeutics Inc?
Projected CAGR
46%
The compound annual growth rate for Net Income over the next 8 years is 46%.
